This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Non-Hodgkin lymphoma
  • /
  • Bi- and Tri-specific antibodies in non-Hodgkin lym...
Journal

Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives

Read time: 1 mins
Published:24th Jan 2024
Author: Abou Dalle I, Dulery R, Moukalled N, Ricard L, Stocker N, El-Cheikh J et al.
Availability: Free full text
Ref.:Blood Cancer J. 2024 Jan 25;14(1):23.
DOI:10.1038/s41408-024-00989-w
Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives 


Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing the treatment landscape of B-cell non-Hodgkin's lymphoma (B-NHL). In the relapsed/refractory setting, salvage chemotherapy and autologous stem cell transplantation are capable of curing 50% of patients, whereas the other half will have a dismal outcome with a median overall survival of less than 12 months. This unmet need reinforced the importance of innovative therapies like the BsAbs and CAR-T cell therapies. In this review, we delve into BsAbs in B-NHL from the preclinical development to clinical data in both refractory and frontline settings, and then discuss future perspectives.


Read abstract on library site  Access full article